Haijun Ma

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Bradley J. Monk, Andrés Poveda, Ignace Vergote et al. · Gynecologic Oncology · 2016 · 96 citations · Full text

Medicine, Gynecology, Oncology +17

Determination of mild, moderate, and severe pain interference in patients with cancer

Qiuling Shi, Tito R. Mendoza, Amylou C. Dueck et al. · Pain · 2017 · 86 citations

Medicine, Oncology, Cancer Pain Management +16

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 86 citations · Full text

Medicine, Gynecology, Oncology +11

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

Christian Marth, Ignace Vergote, Giovanni Scambia et al. · European Journal of Cancer · 2016 · 80 citations

Medicine, Oncology, Pharmacology +13

Bayesian Hierarchical Modeling for Detecting Safety Signals in Clinical Trials

H. Amy Xia, Haijun Ma, Bradley P. Carlin · Journal of Biopharmaceutical Statistics · 2011 · 64 citations

Public Health, Biostatistics, Bayesian Biostatistics +16